The Complete Peptide Dosage Guide

Peptide dosing is frequently misunderstood as a single fixed number, when in reality it is a range shaped by several interacting variables. Because peptides are highly specific signaling molecules — chains of 2–50 amino acids that bind particular receptors — the effective dose for one compound can be a thousand-fold different from another. A cosmetic peptide applied topically at a few percent concentration and an injectable GLP-1 agonist titrated in milligrams are simply not comparable. Understanding the drivers of dosage is therefore more useful than memorizing individual numbers.

The first driver is the compound itself and its potency. Growth hormone secretagogues are active in the microgram (mcg) range, healing peptides typically span hundreds of micrograms to a few milligrams, and metabolic peptides like tirzepatide are dosed in single-digit to mid-double-digit milligrams per week. Molecular weight, receptor affinity, and half-life all influence how much of a compound is required and how often it must be administered. If you are new to these concepts, our overview of what peptides are provides helpful foundations.

The second driver is the research goal. Lower ends of a dosage range are generally associated with maintenance, subtle signaling, or conservative first exposure, while upper ends are associated with more aggressive protocols. Goals are not interchangeable: a dose studied for tissue repair does not automatically apply to metabolic or cosmetic endpoints. This is why category-specific and compound-specific guides matter more than a single global figure.

The third and fourth drivers are body weight and individual tolerance. Some peptides scale loosely with body mass (for example, certain healing protocols are described per kilogram in animal studies), while others use fixed doses regardless of weight. Tolerance is equally important: two people at the same dose can experience very different side-effect profiles. A responsible approach starts at the low end of any range, observes response over days to weeks, and adjusts slowly. This guide is educational only and is not a substitute for professional medical supervision.

Most research peptides are shipped as a lyophilized (freeze-dried) powder that must be reconstituted with bacteriostatic water before any dose can be measured. Reconstitution math is the single most error-prone step in peptide dosing, and a mistake here can mean under-dosing by 90% or over-dosing by ten-fold. The good news is that the arithmetic is straightforward once the relationship between vial content, diluent volume, and syringe units is clear.

The core formula is simple. Concentration (per mL) = total peptide amount ÷ volume of bacteriostatic water added. For example, a 5 mg (5,000 mcg) vial reconstituted with 2 mL of bacteriostatic water yields a concentration of 2,500 mcg/mL. Because doses are drawn with a U-100 insulin syringe where 100 units = 1 mL, each unit on that syringe equals 25 mcg in this example. A 250 mcg dose therefore corresponds to 10 units.

The table below shows common reconstitution scenarios for a typical vial. Adjusting the diluent volume changes the concentration but not the total amount of peptide — adding more water simply spreads the same dose across more units, which can make small doses easier to measure accurately.

To reduce arithmetic errors, many researchers use a dedicated calculator such as our Peptide Lab reconstitution tool, which converts vial size, diluent volume, and target dose directly into insulin-syringe units. Whatever method you use, verify the concentration twice, add bacteriostatic water slowly against the vial wall rather than directly onto the powder, and store the reconstituted vial refrigerated. Tracking doses over time — for instance with a peptide cycle tracker — helps catch inconsistencies before they compound.

Growth hormone (GH) secretagogues are peptides that stimulate the body's own pituitary release of growth hormone, rather than supplying GH directly. This category includes growth hormone-releasing hormone (GHRH) analogs such as CJC-1295, sermorelin, and tesamorelin, as well as ghrelin-mimetic growth hormone-releasing peptides (GHRPs) such as ipamorelin, GHRP-2, and GHRP-6. Because they act in the microgram range, precise measurement matters enormously.

A defining feature of this category is dose timing. GH is released in pulses, with the largest natural pulse occurring during early sleep. For this reason, secretagogues are frequently administered on an empty stomach and around bedtime, since elevated blood glucose and insulin can blunt the GH response. Many protocols also separate injections from meals by roughly 30 minutes to two hours.

Another important distinction is the presence of DAC (Drug Affinity Complex) on some CJC-1295 preparations. CJC-1295 with DAC has a dramatically extended half-life and is dosed weekly in milligrams, whereas the no-DAC version (often called Mod GRF 1-29) is short-acting and dosed multiple times per day in micrograms. Confusing the two is a common and consequential error.

A widely discussed practice is combining a GHRH analog with a GHRP to produce a synergistic GH pulse, a topic covered in our peptide stacking guide. These compounds are research chemicals and are not approved for human enhancement use; anyone considering them should consult a qualified endocrinologist, particularly given effects on blood glucose and insulin sensitivity.

Healing and recovery peptides are among the most searched compounds in this space, led by BPC-157 and TB-500 (a synthetic fragment of Thymosin Beta-4). These peptides are studied primarily in preclinical models for tissue repair, angiogenesis, and cell migration. It is critical to note that despite extensive animal research — over 100 preclinical studies on BPC-157 alone — there are currently zero completed Phase III human clinical trials, so all human dosing is extrapolated and unvalidated.

BPC-157, a 15-amino-acid peptide with a molecular weight of roughly 1,419 Daltons, is typically discussed in the range of 200–500 mcg per day in research protocols, sometimes split into two administrations. It can be delivered subcutaneously near an area of interest or systemically. In rat models, tendon-healing acceleration of 60–80% versus control has been reported, but such figures do not translate directly to validated human doses.

TB-500 follows a different pattern. Because Thymosin Beta-4 is a larger 43-amino-acid protein (MW ≈ 4,963 Da) and TB-500 acts on a longer timescale, protocols often use a loading phase of roughly 2–2.5 mg administered twice weekly for 4–6 weeks, followed by a reduced maintenance dose. The copper peptide GHK-Cu appears in both injectable research contexts (around 1–2 mg) and, far more commonly and safely, in topical cosmetic formulations.

BPC-157 and TB-500 are frequently combined for tissue repair, and the pairing is discussed in more depth in their respective monographs. Regardless of protocol, these are unapproved research peptides; their long-term safety in humans is not established, and their use is not endorsed. Professional medical guidance is strongly recommended before considering any of them.

Cosmetic peptides are dosed in a fundamentally different way from injectable research peptides. Rather than being measured in micrograms per injection, they are formulated at a percentage concentration in a topical product — a serum, cream, or emulsion applied to the skin. This makes them among the most accessible and lowest-risk peptides, and it is why an estimated 8 out of 10 anti-aging skincare products now contain at least one peptide.

The two most established cosmetic peptides are Argireline (Acetyl Hexapeptide-3) and Matrixyl 3000. Argireline is a neuromodulating peptide often included at 5–10% in expression-line serums, where studies report wrinkle-depth reductions of up to 30% over 30 days. Matrixyl 3000, a signal peptide complex, is typically used at 3–8% and has been associated with collagen-synthesis increases of over 100% in manufacturer research. Topical GHK-Cu is generally formulated at 1–2%.

Because these ingredients work at the skin surface and in the upper dermis, "dosage" is really about formulation percentage, application frequency, and layering order. Most cosmetic peptides are applied once or twice daily to clean skin, and they generally pair well with hydrating and barrier-supporting ingredients. Our guides on cosmetic peptides and peptides versus retinol cover formulation and layering in detail.

The safety profile of topical cosmetic peptides is considerably more favorable than that of injectables, since systemic absorption is minimal and the ingredients are used within regulated cosmetic frameworks. Even so, patch-testing new products, introducing one active at a time, and following manufacturer usage instructions remain sensible practices. Results are typically gradual, appearing over weeks of consistent use rather than immediately.

GLP-1 receptor agonists — most prominently semaglutide and tirzepatide — are unique in this guide because they include FDA-approved medications with well-defined titration schedules, unlike the research-only peptides discussed elsewhere. They now account for roughly 60% of all peptide-related search traffic, driven by their substantial effects on appetite and body weight. Our overview of the GLP-1 class explains their mechanism in depth.

The defining principle of GLP-1 dosing is gradual titration. These medications commonly cause gastrointestinal side effects — nausea, reduced appetite, and altered digestion — especially when dosing increases too quickly. To manage this, prescribers begin at a low starting dose and increase in steps every four weeks, allowing tolerance to develop. Starting high is a serious mistake that dramatically increases the risk of adverse effects.

For semaglutide, the approved schedule typically begins at 0.25 mg weekly for four weeks, then increases stepwise (0.5 mg, 1.0 mg, 1.7 mg) toward a maintenance dose of up to 2.4 mg weekly. In clinical trials, semaglutide produced average weight loss of roughly 15–17% of body weight. For tirzepatide, dosing usually starts at 2.5 mg weekly and titrates upward (5, 7.5, 10, 12.5 mg) toward as much as 15 mg weekly, with trial weight-loss averages around 20–22%.

Because these are potent prescription medications with real contraindications and monitoring requirements, GLP-1 titration must be directed by a licensed healthcare provider. The schedules above summarize approved labeling and clinical-trial data for educational purposes; they are not a self-dosing protocol. Individuals should never source or self-titrate these compounds without medical supervision.

Beyond the amount per dose, two scheduling questions determine how a peptide protocol actually unfolds: how often a dose is administered and how long a cycle lasts. These are governed largely by each peptide's half-life. Short-acting peptides such as ipamorelin or no-DAC CJC-1295 clear the body within hours and are dosed one to three times daily, while long-acting compounds such as CJC-1295 with DAC or weekly GLP-1 agonists are dosed just once or twice a week.

Cycle length varies by category and goal. Healing peptide protocols are frequently structured as defined courses — for example, four to eight weeks aligned with a specific recovery objective — after which use is paused. GH secretagogue cycles are often run for 8–12 weeks with breaks, partly to limit receptor desensitization. Cosmetic peptides, by contrast, are used continuously as part of a daily skincare routine, since their benefits depend on ongoing application. GLP-1 use is a long-term, physician-managed therapy rather than a short cycle.

The concept of cycling — periods on followed by periods off — is common in the research-peptide community, motivated by the idea that continuous stimulation of a receptor system may reduce responsiveness over time. Evidence for optimal cycle lengths in humans is limited and largely anecdotal, so specific on/off ratios should be treated as convention rather than established science. Keeping a written record of dose, timing, and response helps identify what actually works for an individual.

The table below summarizes typical scheduling patterns by category. These are general conventions drawn from common protocols and published labeling, not personalized recommendations. Any real protocol should be individualized with professional guidance, factoring in health status, concurrent medications, and goals.

Safe dosage adjustment follows a consistent principle across every peptide category: start low, go slow, and observe. Because individual tolerance varies widely, the lowest end of a published range is almost always the right place to begin. This allows you to establish a baseline response and side-effect profile before considering any increase, and it minimizes the consequences of an unexpected reaction.

Monitoring is central to safe adjustment. Track objective markers where possible — for GLP-1 peptides, that might include weight, appetite, and blood glucose; for GH secretagogues, sleep quality and, under medical supervision, IGF-1 levels; for healing peptides, the recovery endpoint of interest. Note any adverse effects such as injection-site reactions, water retention, headaches, tingling, or gastrointestinal upset. If side effects appear, hold the dose steady or reduce it rather than pushing higher.

Certain situations warrant stopping immediately and seeking medical care: signs of an allergic reaction, significant or persistent gastrointestinal symptoms, unusual swelling, or any symptom that is severe or unexpected. Peptides can interact with existing conditions and medications — for example, GH secretagogues can affect insulin sensitivity, and GLP-1 agonists have specific contraindications — which is why professional oversight is not optional for higher-risk compounds.

Medical and legal disclaimer: This article is for educational purposes only and does not constitute medical advice. The majority of peptides discussed here are classified for research use only and are not approved by the FDA, EMA, or other regulators for human use; their legal status varies by jurisdiction. Much of the supporting evidence comes from animal or preclinical studies rather than human clinical trials. Always consult a qualified healthcare professional before considering any peptide, and review our full medical disclaimer for additional context.